Abstract

This project is part of a Blood and Marrow Transplant Clinical Research Network which is conducting multicenter clinical trials in hematopoietic stem cell transplantation. The purpose of the network is to promote the efficient comparison of novel treatment methods and management strategies of potential benefit for children and adults undergoing blood or marrow transplantation. Studies under development include a comparison of blood versus marrow stem cell transplantation. Studies under development include a comparison of blood versus marrow stem cell transplantation after marrow ablation, the development of non-myeloablative transplant regimens, and the best ways to avoid infections in transplant patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL069254-02
Application #
6527972
Study Section
Special Emphasis Panel (ZHL1-CSR-F (S1))
Program Officer
Peterson, Charles M
Project Start
2001-09-30
Project End
2006-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
2
Fiscal Year
2002
Total Cost
$150,000
Indirect Cost

  Institution

Name
Children's Mercy Hosp (Kansas City, MO)
Department
Type
DUNS #
City
Kansas City
State
MO
Country
United States
Zip Code
64108

  Publications

Shenoy, Shalini; Walters, Mark C; Ngwube, Alex et al. (2018) Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Biol Blood Marrow Transplant 24:1216-1222
Miggelbrink, Alexandra M; Logan, Brent R; Buckley, Rebecca H et al. (2018) B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood 131:2967-2977
Dietz, Andrew C; Savage, Sharon A; Vlachos, Adrianna et al. (2017) Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Ped Biol Blood Marrow Transplant 23:1422-1428
Dietz, Andrew C; Mehta, Parinda A; Vlachos, Adrianna et al. (2017) Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International C Biol Blood Marrow Transplant 23:726-735
Dietz, Andrew C; Duncan, Christine N; Alter, Blanche P et al. (2017) The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation f Biol Blood Marrow Transplant 23:24-29
Dietz, Andrew C; Lucchini, Giovanna; Samarasinghe, Sujith et al. (2016) Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia. Curr Opin Pediatr 28:3-11
Yanik, Gregory A; Grupp, Stephan A; Pulsipher, Michael A et al. (2015) TNF-receptor inhibitor therapy for the treatment of children with idiopathic pneumonia syndrome. A joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biol Blood Marrow Transplant 21:67-73
Lankester, Arjan C; Locatelli, Franco; Bader, Peter et al. (2015) Will post-transplantation cell therapies for pediatric patients become standard of care? Biol Blood Marrow Transplant 21:402-11
Pulsipher, M A; Langholz, B; Wall, D A et al. (2015) Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplant 50:1173-9
Pulsipher, Michael A; Carlson, Chris; Langholz, Bryan et al. (2015) IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood 125:3501-8

Showing the most recent 10 out of 26 publications